Literature DB >> 6421743

Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

C Roy, A Foz, C Segura, M Tirado, M Teixell, D Teruel.   

Abstract

We studied the in vitro activity of ciprofloxacin against 570 strains of ampicillin-resistant Enterobacteriaceae and 286 Pseudomonas aeruginosa strains. 95.26% of the Enterobacteriaceae and 53.45% of the P. aeruginosa were inhibited by 0.1 mg/l of ciprofloxacin. 2 mg/l of ciprofloxacin inhibited all of the Enterobacteriaceae strains and 4 mg/l all of the P. aeruginosa. We compared the activity of ciprofloxacin with that of temocillin in the Enterobacteriaceae strains. In the P. aeruginosa strains, classified according to their susceptibility to carbenicillin and gentamicin, we compared the activity of ciprofloxacin with that of ceftazidime. In the strains studied, the in vitro activity of ciprofloxacin is superior to that of temocillin against the Enterobacteriaceae and to that of ceftazidime against the P. aeruginosa strains.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6421743     DOI： 10.1007/bf01641358

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  8 in total

1.  Acidometric agar plate method for ampicillin susceptibility testing of Haemophilus influenzae.

Authors:  C H Park; J S Lopez; C B Cook
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

Review 2.  The beta-lactamases of gram-negative bacteria and their possible physiological role.

Authors:  M H Richmond; R B Sykes
Journal:  Adv Microb Physiol       Date:  1973       Impact factor: 3.517

3.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

4.  An evaluation of 12 methods for the demonstration of penicillinase.

Authors:  T J Lucas
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

5.  Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors:  H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

6.  In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors:  K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191
  8 in total
  11 in total

1.  Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients.

Authors:  M LeBel; M G Bergeron; F Vallée; C Fiset; G Chassé; P Bigonesse; G Rivard
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors:  J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.

Authors:  H Van Poppel; M Wegge; H Dammekens; V Chysky
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

4.  Ciprofloxacin penetration into extravascular spaces in a rabbit model.

Authors:  K L Nichol; L R Peterson; C E Fasching; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.

Authors:  W Wingender; K H Graefe; W Gau; D Förster; D Beermann; P Schacht
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

Review 6.  Fluorinated quinolones. A review of their mode of action, antimicrobial activity, pharmacokinetics and clinical efficacy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1986-02-21

Review 7.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

8.  Quantitation of ciprofloxacin in body fluids by high-pressure liquid chromatography.

Authors:  A Weber; D Chaffin; A Smith; K E Opheim
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

9.  In vitro activity of ciprofloxacin against aerobic bacteria isolated in a southern European hospital.

Authors:  G Cornaglia; R Pompei; B Dainelli; G Satta
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

10.  Tissue penetration of ciprofloxacin after single and multiple doses.

Authors:  M LeBel; F Vallée; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1986-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.